ED@crukcambridgecentre.org.uk
01223 763384
Members Area
Members Area
ED@crukcambridgecentre.org.uk
01223 763384
Members Area
Members Area
Published: 08th September, 2020
DNA from tissue biopsies taken from patients with Barrett’s oesophagus – a risk factor for oesophageal cancer – could show which patients are most likely to develop the disease eight years before diagnosis, suggests a study led by researchers at the University of Cambridge and EMBL’s European Bioinformatics Institute (EMBL-EBI).
Click on headline above for full story
Published: 10th August, 2020
Congratulations to Professors Antoniou and Brindle and Dr Tischkowitz who have been successful in their recent applications for ACED awards.
Published: 05th August, 2020
The Cytosponge was featured on BBC Look East last night, 4th August, along with a report of the BEST3 trial results.
Published: 31st July, 2020
A ‘sponge on a string’ pill test can identify ten times more people with Barrett’s oesophagus than the usual GP route*, according to a new study funded by Cancer Research UK and published in The Lancet today. The test, which can be carried out by a nurse in the GP surgery, is also better at picking up abnormal cells and potentially early-stage cancer.
Published: 23rd July, 2020
It is with immense sadness we share the news that Sanjiv Sam Gambhir, MD, PhD, has passed away. Sarah Bohndiek, Programme Co-Lead, pays a moving tribute to the scientist in whose lab she spent two years as a postdoctoral researcher.
Published: 26th June, 2020
We are absolutely delighted to announce that Sarah Bohndiek, Co-lead of the Early Detection Programme, will be promoted to Professor from October. Following her PhD at UCL, Sarah began her postdoctoral research in Cambridge under Kevin Brindle in 2008. After a period of 2 years at Stanford under Sam Gambhir, she returned to Cambridge in 2013 as a University Lecturer in the Department of Physics, and was jointly appointed as a group leader at the CRUK Cambridge Institute in 2014.
Published: 18th June, 2020
A new method of analysing cancer patients’ blood for evidence of the disease could be up to ten times more sensitive than previous methods according to new research funded by Cancer Research UK and published in Science Translational Medicine on Wednesday.
In the coming years, this method and others based on this approach could lead to tests that more accurately determine if a patient is likely to relapse after having treatment, and could pave the way for the development of pinprick home blood tests to monitor patients
Published: 22nd May, 2020
In its May International Alliance for Cancer Early Detection (ACED) newsletter, Cancer Research UK is showcasing the first researchers who received Alliance funding. Four projects that are collaborations with members of the Cancer Research UK Cambridge Centre have been awarded ACED Pilot funding and one researcher from the University of Manchester has received the ACED Skills exchange and development travel award to visit Cambridge University.
Published: 20th May, 2020
The expansion of ‘mutant’ cells that could lead to cancer is often kept in check by their neighbours, research from the Wellcome Sanger Institute, the University of Cambridge and their collaborators has found. The team discovered that when equally-matched cells in the oesophagus of mice coincided, they acted as a brake on one another’s growth.
The study, published 18 May 2020 in Nature Genetics, describes the ‘rules of the game’ of competition between oesophageal cells for the first time. By understanding these rules, the hope is that therapies can be developed to reduce the competitiveness of mutant clone cells that are more likely to become cancerous.
Published: 18th May, 2020
It has been truly impressive to read how many Cambridge researchers are stepping up to contribute to the national response to COVID-19 and the Early Detection Programme is no different.